September 26, 2026 · 2 min read
How Many Calories to Bulk: The Numbers That Actually Work on Cycle
Bulk calorie math on cycle: TDEE, the 300-500 surplus rule, macros that matter on gear, and why the scale is the only referee.
Read ArticleNAD+ is not a peptide. This guide explains what it does, how precursors perform in trials, where evidence is strong, and what matters for metabolic health.
Iron Scholar
November 14, 2026 · 7 min read
NAD+ sits at the center of cellular energy production, DNA repair, and a growing list of longevity pathways. Searches for “NAD peptide” have exploded because clinics and online discussions often group injectable NAD+ with actual peptides. The chemistry tells a different story, and the human data are more nuanced than marketing suggests.
This guide cuts through the noise. It explains what NAD+ is, why levels matter, how the main precursors perform in controlled trials, where the evidence is strong versus preliminary, and what practical options look like for people interested in metabolic health, recovery, and healthy aging.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It consists of two nucleotides—one carrying nicotinamide and one carrying adenine—linked by phosphate groups. It is not a chain of amino acids and contains no peptide bonds.
Peptides are short sequences of amino acids joined by peptide bonds. NAD+ is built differently. The confusion arises because many wellness clinics offer compounded injectable NAD+ alongside peptides such as BPC-157, TB-500, or MOTS-c, and search engines treat the terms as related. Accurate terminology matters for understanding mechanisms, regulation, and expected effects.
NAD+ functions primarily as a redox cofactor. In its oxidized form (NAD+) and reduced form (NADH), it shuttles electrons during glycolysis, the Krebs cycle, and oxidative phosphorylation—the processes that generate ATP. Beyond energy metabolism, NAD+ serves as a required substrate for:
When NAD+ availability drops, these enzymes compete for a limited pool. Cells prioritize energy production and DNA repair under stress, which can limit sirtuin activity and other protective pathways.
Preclinical work in rodents consistently shows tissue NAD+ declines with age. Human data are more tissue-specific and less uniform.
Some studies report lower NAD+ in skin, certain brain measurements, and selected other tissues with advancing age. Plasma or whole-blood measurements have produced mixed results. A 2026 analysis of more than 1,000 adults found that whole-blood NAD levels did not decline with chronological age in healthy individuals; they remained stable in males and increased in females. Lower levels were more clearly associated with cardiovascular disease and hypertension than with age itself.
The practical takeaway is that NAD+ biology is context-dependent. Decline appears real in some tissues and conditions, but it is not a simple universal clock that ticks the same way in every person or every organ. Disease, inflammation, metabolic stress, and lifestyle factors influence the picture as much as—or more than—calendar age.
Cells synthesize NAD+ through several routes:
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) feed into the salvage pathway. NR is converted to NMN by nicotinamide riboside kinases; NMN is then converted to NAD+ by NMNAT enzymes. Direct oral NAD+ has poor bioavailability, which is why most supplements and many clinical studies use the precursors.
Multiple randomized trials and systematic reviews have tested NR and NMN. The consistent finding is biochemical target engagement: oral doses raise circulating NAD+ and related metabolites.
Safety and tolerability data are generally favorable across weeks to several months at common study doses (often 250–1,000 mg/day for NMN or NR). Adverse events tend to be mild when they occur.
Functional and clinical outcomes are more mixed. A 2023 review of human NR trials noted that while NAD-related metabolites increase, clinically meaningful effects on insulin sensitivity, energy expenditure, or exercise capacity have often been absent or modest. A 2024 systematic review of NAD and precursors across conditions (chronic fatigue, older adults, Parkinson’s, metabolic issues) reported good tolerability and some signals for quality-of-life measures, reduced anxiety markers, and selected metabolic parameters, while emphasizing the need for more targeted trials.
Specific signals that have appeared in individual trials include:
Null or negative findings are equally important. A large 52-week phase-3 trial of NR (1,000 mg/day) in early Parkinson’s disease found no benefit on the primary clinical score and worse outcomes on some secondary measures compared with placebo. Meta-analyses of physical performance parameters in older adults have often shown little consistent effect of NMN on muscle mass, grip strength, or gait speed. Effects on insulin sensitivity and many metabolic endpoints frequently fail to reach significance when trials are pooled.
Intravenous or intramuscular NAD+ is widely offered in clinics. Rigorous randomized outcome trials for anti-aging or wellness indications remain essentially absent. Pharmacokinetic questions persist about how efficiently extracellular NAD+ enters cells versus how precursors raise intracellular pools.
From a practical training perspective, NAD+ supports mitochondrial function and cellular energy. Resistance training and high-intensity work create metabolic stress that can temporarily alter NAD+ dynamics. Some athletes and coaches experiment with precursors or injectable forms for recovery and perceived energy.
Current controlled evidence does not show reliable gains in muscle mass, strength, or aerobic capacity from standard oral precursor doses. Any benefits are more likely to appear as support for cellular recovery processes rather than direct anabolic or performance-enhancing effects comparable to established training and nutrition levers. Lifestyle factors that support NAD+ biology—resistance training, adequate sleep, protein intake, and metabolic health—remain foundational.
The most evidence-based approach begins with the fundamentals that influence NAD+ status and overall metabolic resilience:
Oral NR and NMN can raise circulating NAD+ markers and have a favorable short-term safety profile in studied populations. They represent tools rather than proven anti-aging drugs. Dosing in trials has typically ranged from 250 mg to 1,000+ mg daily; individual responses and optimal long-term regimens are still being clarified. Product quality, third-party testing, and realistic expectations matter.
Injectable NAD+ carries higher cost, more variable regulation depending on jurisdiction, and thinner outcome data. It may produce different pharmacokinetics, but claims of superior tissue delivery require stronger human evidence.
Emerging research continues to explore tissue-specific delivery, combinations with other interventions, and more precise patient selection. Larger, longer trials with clinically meaningful endpoints will determine which populations, if any, derive clear benefit.
The field has genuine biological interest and clear target engagement with precursors. It also has a gap between rodent results, circulating biomarkers, and consistent human functional outcomes. Marketing often outruns the data. Age-related NAD+ decline is real in some contexts and less consistent in others. Safety looks good so far, but long-term data in diverse populations remain limited.
Readers benefit most from treating NAD+ support as one element of a broader strategy focused on training, recovery, metabolic health, and evidence-based lifestyle choices. The science is advancing. The opportunity lies in continuing rigorous research while applying what is already known about human physiology.
No. It is a dinucleotide coenzyme. The “NAD peptide” search term reflects clinic packaging and online discussion more than chemistry.
Yes. Multiple trials show reliable increases in circulating NAD+ and related metabolites at studied doses.
No human trial has demonstrated reversal of aging. Some studies show modest improvements in selected markers or functional tests; many others are null. Claims of broad anti-aging effects exceed the current evidence.
It produces different pharmacokinetics, but rigorous comparative outcome data for wellness or longevity endpoints are lacking. Oral precursors have clearer safety and biomarker data from controlled trials.
Oral NR and NMN have been well tolerated in short-to-medium-term studies. Mild side effects occasionally occur. Long-term safety data and interactions with specific medical conditions still require more research. Consult a physician before starting any new supplement, especially if you have health conditions or take medications.
Training, sleep, body composition, and metabolic health remain the highest-leverage factors supported by the broadest evidence.
The current evidence positions NAD+ as a legitimate area of metabolic and aging research with clear biochemical activity from precursors and a need for more definitive clinical outcome trials. Supporting the pathways through lifestyle remains the most reliable foundation while the science continues to mature.
The Real Talk
Put your name and email in. Get the unfiltered intel on cycles, compounds, dosages, PCT, sides, and what actually works when you're on gear. No motivational posters. No "just train harder." Just the real talk for people who pin.
No spam. No fluff. Unsubscribe anytime.
September 26, 2026 · 2 min read
Bulk calorie math on cycle: TDEE, the 300-500 surplus rule, macros that matter on gear, and why the scale is the only referee.
Read Article
September 26, 2026 · 2 min read
Carb cycling explained for lifters: high days on training legs, low days on rest, and why insulin sensitivity decides whether it's a tool or a trend.
Read Article
September 12, 2026 · 7 min read
How to eat on cycle: the anabolic diet for muscle gain, calories, macros, and meal timing. Steroids amplify your building; food does the building. Here's…
Read Article